Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC

Abroad (travel likely)RecruitingPHASE2

Conditions

Recurrent or Metastatic Nasopharyngeal Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Fifth affiliated hosptial of Sun-yat Sen university, Zhuhai, Guangzhou, China
Contact: Study coordinator (Mingyuan Chen, MD, PhD) · chmingy@mail.sysu.edu.cn · 18124188280

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial

Recurrent or Metastatic Nasopharyngeal Carcinoma

Abroad (travel likely)RecruitingPHASE2

Guangzhou, China · Guangzhou, China

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

Metastatic Nasopharyngeal Carcinoma · Recurrent Nasopharyngeal Carcinoma · Stage IV Nasopharyngeal Carcinoma AJCC v8

Abroad (travel likely)RecruitingPHASE2

Dublin, United States · Fremont, United States

Sintilimab Combined With Anlotinib and Taxane-Based Chemotherap for Recurrent/Metastatic Nasopharyngeal Carcinoma

Recurrent or Metastatic Nasopharyngeal Carcinoma

Abroad (travel likely)RecruitingPHASE2

Zhuhai, China

A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.

Recurrent or Metastatic Nasopharyngeal Carcinoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Chongqing, China · Fuzhou, China